ArticleResearch and practice in thrombosis and haemostasis2023

Treatment switch to nonacog beta pegol factor IX in hemophilia B: A Canadian cost-consequence analysis based on real-world factor IX consumption and clinical outcomes.

Alfonso Iorio et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.